LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

8.28 -0.24

Overview

Share price change

24h

Current

Min

8.27

Max

8.46

Key metrics

By Trading Economics

Income

5.1M

5.1M

Sales

18M

163M

Profit margin

3.113

Employees

580

EBITDA

-84M

-62M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+110.59% upside

Dividends

By Dow Jones

Next Earnings

3 lis 2025

Market Stats

By TradingEconomics

Market Cap

-88M

1.7B

Previous open

8.52

Previous close

8.28

News Sentiment

By Acuity

32%

68%

94 / 371 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 wrz 2025, 23:07 UTC

Acquisitions, Mergers, Takeovers

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2 wrz 2025, 22:10 UTC

Major Market Movers

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2 wrz 2025, 21:47 UTC

Earnings

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2 wrz 2025, 16:52 UTC

Major Market Movers

CleanCore Solutions Shares Drop After $175 Million Private Investment

2 wrz 2025, 22:47 UTC

Market Talk

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2 wrz 2025, 21:40 UTC

Acquisitions, Mergers, Takeovers

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2 wrz 2025, 21:07 UTC

Earnings

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2 wrz 2025, 21:07 UTC

Earnings

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2 wrz 2025, 21:05 UTC

Earnings

Couche-Tard 1Q Rev $17.35B >ATD.T

2 wrz 2025, 21:05 UTC

Earnings

Couche-Tard 1Q Adj EPS 78c >ATD.T

2 wrz 2025, 21:05 UTC

Earnings

Couche-Tard 1Q EPS 82c >ATD.T

2 wrz 2025, 21:05 UTC

Earnings

Couche-Tard 1Q Net $782.5M >ATD.T

2 wrz 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

2 wrz 2025, 20:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2 wrz 2025, 20:51 UTC

Acquisitions, Mergers, Takeovers

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 wrz 2025, 20:27 UTC

Earnings

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2 wrz 2025, 20:24 UTC

Acquisitions, Mergers, Takeovers

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2 wrz 2025, 20:18 UTC

Acquisitions, Mergers, Takeovers

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2 wrz 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2 wrz 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2 wrz 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2 wrz 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2 wrz 2025, 19:55 UTC

Earnings

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2 wrz 2025, 19:50 UTC

Acquisitions, Mergers, Takeovers

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2 wrz 2025, 19:09 UTC

Market Talk

Oil Futures Gain on Geopolitical Premium -- Market Talk

2 wrz 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2 wrz 2025, 18:12 UTC

Market Talk

Gold Pushes To New Record -- Market Talk

2 wrz 2025, 17:04 UTC

Market Talk

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2 wrz 2025, 16:57 UTC

Acquisitions, Mergers, Takeovers

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

110.59% upside

12 Months Forecast

Average 17.5 USD  110.59%

High 30 USD

Low 12 USD

Based on 6 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Sentiment

By Acuity

94 / 371 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.